~~<i id='8E4307AFFA'><strike id='8E4307AFFA'><tt id='8E4307AFFA'><pre id='8E4307AFFA'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：knowledge 2025-09-29 13:34:25 Page View：6377

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Military medical care influenced by rank and race, new study finds
Next article： Dobbs anniversary: the lost opportunity of abortion as health care

explore

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Venture capitalist Bob Kocher on the state of digital health

BobKocher,apartneratventurecapitalfirmVenrock,speakingatSTAT'sBreakthroughSummitinSanFrancisco.Sarah

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

Readers respond to H5N1 and livestock movements, and more

MollyFergusonforSTATToencouragerobust,good-faithdiscussionaboutdifficultissues,STATpublishesselected